Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
Isabelle Deshaies1, Jovenel Cherenfant1, Niraj J Gusani1, Yixing Jiang2, Harold A Harvey2, Eric T Kimchi1, Jussuf T Kaifi1, Kevin F Staveley-O’Carroll11Program for Liver, Pancreas and Foregut Tumors, Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA; 2De...
Main Authors: | Isabelle Deshaies, Jovenel Cherenfant, Niraj J Gusani, et al |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-09-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/gastrointestinal-stromal-tumor-gist-recurrence-following-surgery-revie-a5351 |
Similar Items
-
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
by: Richard Quek, et al.
Published: (2010-02-01) -
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01) -
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
by: Adnan Asif Parvez Ghias, et al.
Published: (2018-03-01) -
Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
by: Hiroyuki Sako, et al.
Published: (2014-01-01) -
A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome
by: Jiang Ming, et al.
Published: (2010-05-01)